Pharmababble
Biomedical investment and business development chatter
RSS Feed
Home
About
Archives
Biopharma BD
Life Sci Stocks
Contact
// Contact
Your Name
(required)
Email
(valid email required)
Website
Message
cforms
contact form by delicious:days
Share and Enjoy:
Categories
Clinical Trial Results
Closing Bell
Company Shakeups
FDA/Regulatory
Financial
funding
Intellectual Property
IPO
License/Partnership
M&A
Media
Politics
Restructurings and Layoffs
Rumors
Sales/Marketing
Science
Statistics
Uncategorized
Venture Capital
Video
Recent Comments
Kay on
Accera Completes $35 Million Series C Financing
Archer Pharmaceuticals Launches to Target Alzheimer’s Disease | Pharmababble
on
Bapineuzumab Fails Trial
Archer Pharmaceuticals Launches to Target Alzheimer’s Disease | Pharmababble
on
Myriad Cancels Flurizan Development
The Swami Was Right: Lilly Buys ImClone | Pharmababble
on
Swami Predicts ImClone’s Future
Mike Shaddick on
MS News: Fingolimod (FTY720) Open Label Results and Tysabri PML Data
Honors and Affiliations
Blogroll
business|bytes|genes|molecules
Colorado Life Science Deal Flow
Deal Lawyers
Drug Wonks
Eye on FDA
Futile Cycle
Health Business Blog
In The Pipeline
My Biotech Life
My Google Reader Feed
On Pharma
One Med Place
Orange Book Blog
Patent Baristas
Pharma Marketing Blog
Pharma’s Market
PharmaGossip
Pharmalot
The Biotech Weblog
The Health Care Blog
The In Vivo Blog
The Physician Executive
Venture Beat
WSJ Health Blog
Recent Comments